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Innovations
Xanthus Life Sciences
Fine-Tuning Personalized Medicine
perspective, these metabolic pro- tin,” says Boss. But Boss adds that
Xanthus’ purpose differs in that theirfiles explain differences in therapeu-
tic efficacy and unpredictable risks technology does not select for who
In 2001, Xanthus Life Sciences won
a beauty contest of sorts. It was se-
lected to receive $10.6 million Series
A venture financing lead by Health for side effects in individual patients. should or should not be given a drug.
Care Ventures and others to fully op- “We focused on cancer in particu- “The idea is to be able to give it to
timize its mission of creating truly lar because it is important to bring in everybody,” he says. “This is very
personalized anticancer medicines. some new technology to make sure different from the traditional phar-
Xanthus began its life as a ven- everyone is getting the biggest ‘hit’ macogenomics approach that se-
ture out of McGill University in Mon- they can take or that they are switched lects which subgroup of patients
treal under the guidance of Brian to other medications depending on should receive the drug. Instead, we
Leyland-Jones, MD. When the ven- what they are likely to respond to,” are trying to figure out how to give
ture community selected Xanthus to says Ajami. Historically, antineo- everybody the dose that is right for
receive funding, they also selected plastics have a 20% to near 100% them.”
another complementary company, response failure rate, and Xanthus Ajami explains that using a spe-
Phenome Sciences, based in Mas- believes it has found a way to boost cific sensor, or probe, to test biologi-
sachusetts. The two were merged the efficacy and safety of cancer cal parameters is a way to figure out
into the present-day 40-person Xan- drugs by determining beforehand your phenotype without having to do
thus Life Sciences, headquartered what the appropriate dose may be a lot of genetics or other exams.
in Cambridge, Massachusetts, with for any given patient. Xanthus is developing straightfor-
Leyland-Jones as CEO. Phenome ward tests to determine how an indi-
founder Alfred Ajami, PhD, is now vidual might metabolize a known
Chief Scientific Officer. drug and also assess what the po-“When you look at the en-“The original Xanthus had the tential side effects of a molecule
clinical side and Phenome had the tire pie of what affects a may be. “We have to determine who
scientific platform,” says Chief Op- will be most susceptible to the sidedrug’s response, geno-
erating Officer Michael A. Boss, effects or more susceptible to thetype provides only a mi-PhD. Leyland-Jones had been a re- primary efficacy,” says Ajami.
searcher at the National Cancer In- nority of the variability in Ajami has spent much of his ca-
stitute (NCI), Memorial-Sloan Ketter- reer looking at metabolic pathwaysand amongst us. Also in-
ing Cancer Center, and ultimately searching for control points to probevolved are physiology,the founding chairman of oncology with a pro-drug or a probe sub-
at McGill. “That is where he had the metabolic, biology, and stance to allow him to tune in to
vision that we have to do better than some key transformation that wouldepigenomic factors such
one size fits all in cancer treatment,” be an appraisal of the entire system.as diet, polypharmacy,says Boss, “and Alfred had devel- “We are now able functionally to fig-
oped a broad set of scientific solu- and enzyme induction.” ure out if someone is a high, low,
tions and technology looking for a
or medium responder,” says Ajami.–Alfred Ajami, PhD, Chiefproblem.
“The implications of that is the indi-Scientific Officer, XanthusSmall Molecules for Cancer
vidualized dose to be taken for maxi-The mission at Xanthus is to develop
mum benefit and safety.”drugs that utilize its personalized
It does not hurt that FDA Commis-Test/Drug Combinationmedicine technology platform, be-
sioner Mark McClellan made a state-Leyland-Jones was a coprincipal in-ginning in the oncology arena with
ment in January 2003 effectively con-vestigator on the study that identi-drugs that have previously stalled in
firming Xanthus’ business model.fied the Her2-targeting drug trastu-development elsewhere. “By opti-
“Certain new therapies will be devel-zumab (manufactured by Genentechmizing the dose for each person,”
oped along with tests that can iden-as Herceptin), a drug for breast can-says Boss, “everyone receives the
tify the responding subpopulation,cer with efficacy in roughly 20% ofcorrect individualized dose that will
detect individuals who need a differ-all women who have the disease.achieve maximum therapeutic ben-
ent dose, or find people who arePatients must be tested for the pres-efit and minimize risk of serious ad-
prone to a certain toxic effect,” saidence of HER-2/neu protein to deter-verse drug events.” Behind this plan
McClellan. In addition, he went on tomine if they are eligible for trastuzu-is the phenotypic reality that individ-
confirm that “development of thesemab treatment. “The paradigm of auals metabolize drugs at different
test/therapy combinations must betest/drug combination has now beenrates and that drugs trigger unique
metabolic events. From Xanthus’ proven and accepted with Hercep- facilitated because they have the
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potential to maximize drug benefits bolic probe test had to be developed Xanthus also plans to develop
amonafide for prostate cancer treat-while minimizing toxicity.” to determine appropriate dosing. In
this case, the probe is caffeine. “Caf-Functional Phenotyping ment. Behind amonafide is C-1311,
primarily for colorectal cancer, and“When you look at the entire pie of feine is metabolized in a similar way
to amonafide,” says Ajami; both arewhat affects a drug’s response, ge- DMPEN for brain tumors. Clinical
studies have not begun with thesenotype provides only a minority of metabolized by N-acetyl-transferase
2 (NAT2). “If you are a fast caf-the variability in and amongst us,” programs.
Wide—yet Narrow—says Ajami. “Also involved are physi- feine metabolizer, you are going to
be a fast metabolizer of the cancerology, metabolic, biology, and epi- Applicability
“This approach is extendable to agenomic factors such as diet, poly- drug,” according to Ajami, which will
lead to side effects if the dosing ispharmacy, and enzyme induction.” large number of drugs in a variety of
therapeutic areas, but not any drug,So the company is creating a bio- not adjusted beforehand. “You take
the probe before you start therapychemical equivalent of a treadmill though,” says Ajami. “It has to be a
drug with a narrow therapeutic indexstress test as a probing strategy to to figure out where you fit into a pop-
ulation distribution and therefore de-see what happens phenotypically where dosing is critical to avoid dan-
gerous side effects without under-when an individual is presented with termine what is the right dose.” A
potential amonafide patient is givena surrogate stand-in for the drug in dosing patients who can tolerate a
larger dose.” And it is no small featquestion. “The beauty of the Xan- 100 mg caffeine. Urine specimens
are collected and analyzed to as-thus strategy is that you do not need to develop the probing technology
for each drug, a key requirement ofto understand what is going on in sess the level of metabolites to de-
termine the correct amonafide dos-each of these complicated areas be- the Xanthus strategy. “Each probe/
drug is a specific combination, andcause what we are focusing on is an ing. “This is the general approach
we are validating in our clinical trialsapparently simple integrated out- we would need to demonstrate the
effectiveness of each particularput,” explains Boss. for all our drugs,” says Ajami.
Lead Drug CandidatesThe sensor technology delivers a combination,” says Boss.
Aside from the three anticancersimple measurement of function. Amonafide is being scrutinized in a
127-person phase IIB clinical trial for“Once you know where it is you want drugs currently in play, Xanthus is
interested in collaborating with com-to probe, you can find the appro- metastatic breast cancer. In patients,
the drug is processed by NAT2 to anpriate probe through molecular in- panies with drugs that may benefit
from the boost this sensor/drugformatics,” explains Ajami. In the acetylated form (N-acetyl-amonaf-
ide), and both forms have anticancerclinic, a patient would be given a model may be able to provide. “Our
view of development is to rejuvenatemetabolic sensor probe, and urine, properties; however, the acetylated
form also has myelosuppressiveplasma, or breath would be col- molecules that are already there
from the treasure trove of the past,”lected thirty minutes to several side effects. “Individuals differ in
their rate of NAT2 metabolism byhours after ingesting the probe. The explains Ajami.
metabolized compounds are mea- some 200-fold,” says Boss, and
Chemistry & Biology invites yoursured and analyzed to provide a therefore people with high NAT2 ac-
comments on this topic. Pleasemetabolic profile similar to a bar- tivity may make higher amounts of
write to the editors at chembiol@code. “Individuals have different the acetylated form with its un-
cell.com.barcodes, and so clinically you would wanted myelosuppressive property.
A clinical study of the response ofthen make some judgements as to Alice A. McCarthy is a freelance science
the dose of the therapeutic drug to 73 patients to amonafide found that writer based in Gloucester, MA (alice@
alicemccarthy.com).give to end up in the same place in 18% of these individuals responded
positively to the drug. Xanthus ex-regard to the desired pharmacoki-
netic model,” says Ajami. amined the NAT levels in these pa-
tients. “If you look at the group“We have developed the probe
science and are now applying it with whose NAT2 levels were in the mid-
dle of the range, these women hadlateral flow technology by building
antibodies to each of the small mole- myelosuppression but it was not too
severe,” says Boss. “And they alsocules we are analyzing,” says Ajami.
Xanthus uses immunorecognition had a [positive] response rate of ap-
proximately 35% [to the drug].” Thetechniques to ultimately develop
point-of-use devices (a reader plus aim with amonafide at Xanthus is to
find the correct individual dose—a data processor) akin to devices al-
ready available for therapeutic drug from 100–400 mg/M2—to bring ev-
eryone into this middle range.monitoring using a drop of urine or
blood as the analyte. “Rapid metabolizers start out on the
lower dose, and slow metabolizersI’ll Take Mine Black
Xanthus’ lead drug is the well-known will start out on a higher dose which
is about 33%–50% higher than theanticancer medicine amonafide (XLS-
001) developed in the late 1980s at dose you would have received pre-
viously, when you would have beenthe NCI. But before amonafide could
gain any traction at Xanthus, a meta- underdosed,” explains Ajami.
